DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Allergic Eye Disease Tear Mediators

Information source: University of Wisconsin, Madison
ClinicalTrials.gov processed this data on August 23, 2015
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Allergic Eye Disease

Intervention: olopatadine (Drug)

Phase: N/A

Status: Recruiting

Sponsored by: University of Wisconsin, Madison

Official(s) and/or principal investigator(s):
Neal P Barney, MD, Principal Investigator, Affiliation: University of Wisconsin, Madison


The purpose of the research is to determine which inflammatory substances are involved in causing allergic symptoms in the eye. Allergic conjunctivitis is a common problem with symptoms of temporary redness, itching, tearing, and swelling of the eyes. Substances released by cells in the affected tissues cause allergic reactions in the eye and elsewhere in the body.

Clinical Details

Official title: Expression of Inflammatory Mediators in Allergic Conjunctivitis

Study design: Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science

Primary outcome: tear cytokine concentrations with and without treatment

Secondary outcome: conjunctival epithelial cell surface marker measured with and without treatment

Detailed description: Ocular allergies are extremely common, affecting up to 80 million people in the USA. Our research question is: Are there differences in inflammatory mediators and cell surface activation markers in patients undergoing seasonal allergic conjunctivitis compared to those with sight threatening disease such as Atopic Keratoconjunctivitis (AKC) and will the use of the anti-allergy eye drop, PATANOLĀ® (olopatadine hydrochloride) affect these parameters? Experimental Design: Ocular surface cells (by impression cytology) and tears (via capillary tube) are collected from allergic, non-allergic, and AKC subjects undergoing an reaction induced either by seasonal allergen or topical allergen provocation (specificity and dose determined via skin testing). Ocular surface cells are evaluated for surface activation markers. Tears are evaluated for mediator content. Tears are also incubated with peripheral blood eosinophils and lymphocytes to see effects on adhesion to conjunctival epithelial cells.


Minimum age: 18 Years. Maximum age: 65 Years. Gender(s): Both.


Inclusion Criteria:

- Skin test positive

- Able to put drops in eyes

- Able to have tears collected

Locations and Contacts

University of Wisconsin, Madison, Wisconsin 53705, United States; Recruiting
Neal P Barney, MD, Phone: 608-263-7681, Email: npbarney@wisc.edu
Jim Stahl, PhD, Phone: 608-263-6177, Email: jlstahl@medicine.wisc.edu
Neal P Barney, MD, Principal Investigator
Frank M Graziano, MD PhD, Sub-Investigator
Ellen B Cook, PhD, Sub-Investigator
Jim Stahl, PhD, Sub-Investigator
Additional Information

Related publications:

Cook EB. Tear cytokines in acute and chronic ocular allergic inflammation. Curr Opin Allergy Clin Immunol. 2004 Oct;4(5):441-5. Review.

Starting date: September 2000
Last updated: October 30, 2008

Page last updated: August 23, 2015

-- advertisement -- The American Red Cross
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017